Concern over potential drug shortages arose after a Texas-based doctor licensed in Nova Scotia wrote 17,000 prescriptions for Ozempic for people living in the United States.
A patent cliff refers to the end of IP protection for a drug that has enjoyed market exclusivity since its launch. Between now and 2030, the biopharma sector is expected to be rocked by a number of high profile patent cliffs that are likely to reshape the market.